{"id":5942,"date":"2025-06-09T21:21:42","date_gmt":"2025-06-09T21:21:42","guid":{"rendered":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/?page_id=5942"},"modified":"2025-12-30T14:18:34","modified_gmt":"2025-12-30T14:18:34","slug":"stock-market-information","status":"publish","type":"page","link":"https:\/\/bioceltix.com\/en\/investor-relations\/stock-market-information\/","title":{"rendered":"Stock Market Information"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Stock Market Information<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tGo back to Investor Relations<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tImportant financial data<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tFinancial statements<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tInformation<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Important financial data<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/td>\nParticulars<\/td>\n31.12.2024<\/td>\n31.12.2023<\/td>\n<\/tr>\n
in thousands of PLN<\/td>\nin thousands of EUR<\/td>\nin thousands of PLN<\/td>\nin thousands of EUR<\/td>\n<\/tr>\n<\/thead>\n
1.<\/td>\nNet revenues from product sales<\/td>\n0,00<\/td>\n0,00<\/td>\n0,00<\/td>\n0,00<\/td>\n<\/tr>\n
2.<\/td>\nOperating profit (loss)<\/td>\n-15 033,84<\/td>\n-3 492,83<\/td>\n-14 015,08<\/td>\n-3 094,93<\/td>\n<\/tr>\n
3.<\/td>\nGross profit (loss)<\/td>\n-14 867,41<\/td>\n-3 454,16<\/td>\n-13 692,82<\/td>\n-3 023,76<\/td>\n<\/tr>\n
4.<\/td>\nNet profit (loss)<\/td>\n-14 897,94<\/td>\n-3 461,26<\/td>\n-13 687,55<\/td>\n-3 022,60<\/td>\n<\/tr>\n
5.<\/td>\nNet cash flow from operating activities<\/td>\n-17 567,38<\/td>\n-4 081,45<\/td>\n-14 747,69<\/td>\n-3 256,71<\/td>\n<\/tr>\n
6.<\/td>\nNet cash flow from investing activities<\/td>\n-84,24<\/td>\n-19,57<\/td>\n-458,35<\/td>\n-101,22<\/td>\n<\/tr>\n
7.<\/td>\nNet cash flow from financing activities<\/td>\n41 974,18<\/td>\n9 751,91<\/td>\n20 396,28<\/td>\n4 504,08<\/td>\n<\/tr>\n
8.<\/td>\nTotal net cash flow<\/td>\n24 322,56<\/td>\n5 650,89<\/td>\n5 190,24<\/td>\n1 146,15<\/td>\n<\/tr>\n
9.<\/td>\nNet earnings (loss) per ordinary share (in PLN\/EUR)<\/td>\n-3,28<\/td>\n-0,76<\/td>\n-3,49<\/td>\n-0,77<\/td>\n<\/tr>\n
10.<\/td>\nDiluted net earnings (loss) per ordinary share (in PLN\/EUR)<\/td>\n-3,28<\/td>\n-0,76<\/td>\n-3,49<\/td>\n-0,77<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u00a0<\/p>
\u00a0<\/td>Particulars<\/td>31.12.2024<\/td>31.12.2023<\/td><\/tr>
in thousands of PLN<\/td>in thousands of EUR<\/td>in thousands of PLN<\/td>in thousands of EUR<\/td><\/tr><\/thead>
1.<\/td>Total assets<\/td>41 854,21<\/td>9 795,04<\/td>12 735,30<\/td>1 2 929,00<\/td><\/tr>
\u2013 including cash<\/td>33 632,84<\/td>7 871,01<\/td>9 310,28<\/td>2 141,28<\/td><\/tr>
2.<\/td>Liabilities and provisions for liabilities<\/td>3 436,11<\/td>804,14<\/td>2 268,58<\/td>521,75<\/td><\/tr>
3.<\/td>Long-term liabilities<\/td>149,55<\/td>35,00<\/td>76,33<\/td>17,56<\/td><\/tr>
4.<\/td>Short-term liabilities<\/td>2 910,25<\/td>681,08<\/td>1 888,80<\/td>434,41<\/td><\/tr>
5.<\/td>Equity<\/td>38 418,10<\/td>8 990,90<\/td>10 466,72<\/td>1 2 407,25<\/td><\/tr>
6.<\/td>Share capital<\/td>492,45<\/td>115,25<\/td>412,95<\/td>94,97<\/td><\/tr>
7.<\/td>Number of shares (pcs.)<\/td>4 924 468,00<\/td>4 129 468,00<\/td><\/tr>
8.<\/td>Weighted average number of shares (pcs.)<\/td>4 536 770,00<\/td>3 919 118,00<\/td><\/tr>
9.<\/td>Book value per share (PLN\/EUR)<\/td>7,80<\/td>1,83<\/td>2,53<\/td>0,58<\/td><\/tr>
10.<\/td>Diluted book value per share (PLN\/EUR)<\/td>7,80<\/td>1,83<\/td>2,53<\/td>0,58<\/td><\/tr><\/tbody><\/table>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Financial statements<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t